Article
Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation.
Cells - 14 Jul 2022
Nishihara Shigetoshi, Yamaoka Toshimitsu, Ishikawa Fumihiro, Ohmori Tohru, Ando Koichi, Kusumoto Sojiro, Kishino Yasunari, Manabe Ryo, Hasebe Yuki, Sagara Hironori, Yoshida Hitoshi, Tsurutani Junji
Abstract excerpt
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is used as a first-line treatment for patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, the mechanisms underlying its anticancer activity, particularly the subsequent development of acquired resistance, are unclear. Herein, we investigated the mechanisms underlying the development of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.